Sugi Predict

Sugi Predict / Compounds / SCHEMBL649929

SCHEMBL649929

SCHEMBL649929

NS(=O)(=O)n1ccc2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 5/20 0.61
▸ HTT P42858 4/20 0.61
▸ KMT2A Q03164 3/20 0.61
▸ MEN1 O00255 2/20 0.61
▸ LMNA P02545 2/20 0.61
▸ TSHR P16473 2/20 0.61
▸ ALDH1A1 P00352 1/20 0.61
▸ HPGD P15428 1/20 0.61
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ PKM P14618 1/20 0.54
▸ MAPT P10636 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ RAPGEF4 Q8WZA2 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ CDK4 P11802 3/20 0.42
▸ CCND1 P24385 3/20 0.42
▸ NOTUM Q6P988 1/20 0.41
▸ RAB9A P51151 1/20 0.39
▸ PRKD3 O94806 1/20 0.39
▸ PRKCG P05129 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8415487 0.83 HTR6 (0.66) HTR6HTTKMT2AMEN1LMNA
SCHEMBL6359369 0.80 HTR6 (0.58) HTR6HTTKMT2AMEN1LMNA
SCHEMBL5636978 0.79 HTR6 (0.61) HTR6HTTKMT2AMEN1LMNA
SCHEMBL4065276 0.79 HTR6 (0.61) HTR6HTTKMT2AMEN1LMNA
SCHEMBL29558089 0.79 HTR6 (0.61) HTR6HTTKMT2AMEN1LMNA
SCHEMBL24596834 0.79 HTR6 (0.61) HTR6HTTKMT2AMEN1LMNA
Benzene SCHEMBL29208974 0.78 HTR6 (0.65) HTR6HTTKMT2AMEN1LMNA
SCHEMBL6359366 0.77 HTR6 (0.54) HTR6HTTKMT2AMEN1LMNA
SCHEMBL10433225 0.76 HTR6 (0.58) HTR6HTTKMT2AMEN1LMNA
SCHEMBL29558135 0.76 HTR6 (1.00) HTR6HTTKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106661000-B EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2019-04-09 — — CN disclosed
WO-2018015445-A1 SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY NodThera Limited (GB) 2018-01-25 — — WO disclosed
EP-3272739-A1 SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY NodThera Limited (GB) 2018-01-24 — — EP disclosed
EP-2550257-A1 PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES Lead Discovery Center GmbH (DE) 2013-01-30 — — EP disclosed
US-8119683-B2 Aryl substituted sulfonamide compounds and their use as anticancer agents TAIPEI MEDICAL UNIVERSITY (TW) 2012-02-21 — — US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 — — US disclosed
WO-2011116951-A1 PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES LEAD DISCOVERY CENTER GMBH (DE) 2011-09-29 — — WO disclosed
US-20110039880-A1 ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TAIPEI MEDICAL UNIVERSITY (TW) 2011-02-17 — — US disclosed
WO-2011019634-A2 ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TAIPEI MEDICAL UNIVERSITY (TW) 2011-02-17 — — WO disclosed
CN-101304992-A 1, 3-disubstituted indole derivatives for use as PPAR modulators PLEXXIKON INC (US) 2008-11-12 — — CN disclosed
US-20070072904-A1 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders PLEXXIKON INC 2007-03-29 — — US disclosed
WO-2007030559-A2 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS PLEXXIKON, INC. (US) 2007-03-15 — — WO disclosed
CN-1867547-A Compounds having crth2 antagonist activity OXAGEN LTD (GB) 2006-11-22 — — CN disclosed
EP-1675826-A1 COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY Oxagen Limited (GB) 2006-07-05 — — EP disclosed
WO-2005040114-A1 COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY OXAGEN LIMITED (GB) 2005-05-06 — — WO disclosed
WO-2004113301-A1 GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS GLAXO GROUP LIMITED (GB) 2004-12-29 — — WO disclosed
EP-0227823-B1 COLOR TRANSFER PHOTOGRAPHIC PROCESSES AND PRODUCTS POLAROID CORPORATION (US) 1989-03-22 — — EP disclosed
EP-0227823-A1 COLOR TRANSFER PHOTOGRAPHIC PROCESSES AND PRODUCTS. POLAROID CORP (US) 1987-07-08 — — EP disclosed
WO-1987000307-A1 COLOR TRANSFER PHOTOGRAPHIC PROCESSES AND PRODUCTS POLAROID CORPORATION (US) 1987-01-15 — — WO disclosed
US-4615966-A Color transfer photographic processes and products with indole phthalein filter dyes POLAROID CORPORATION (US) 1986-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072904-A1 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders PPARG, PPARA, PPARD HTR6 178/4885HTT 1140/4885KMT2A 2335/4885
US-20110039880-A1 ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS ARSA, SULT1E1, STS HTR6 3466/4885HTT 3288/4885KMT2A 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.